Biotech Values

[mcbio]

Compared to insulin analog alone, PH20 insulin analog use resulted in a greater than 50% increase in the proportion of patients able to consistently achieve AACE (American Association of Clinical Endocrinologists) guidelines for post-prandial glucose targets in both Type 1 and Type 2 patients.

What specifically are the AACE guidelines? And how meaningful is such an increase in the proportion of patients able to achieve these guidelines?

Across all of the treatment groups, there was no meaningful difference in hypoglycemia incidence or event rates.

Isn't this a negative outcome for HALO's insulin analog? Isn't the point behind a "better" analog being to reduce hypoglycemia incidence or event rates rather than having no meaningful difference?